Skip to main content
AURX
OTC Industrial Applications And Services

Nuo Therapeutics Reports Strong Q1 Revenue Growth Amid Critical Cash Shortage, Secures $1M Loan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.35
Mkt Cap
$65.191M
52W Low
$0.936
52W High
$3.23
52W Position info
44% above low
Off High info
58% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

AURX sits 44% above its 52-week low of $0.936 on elevated volume (2.3× avg).

Summary

Nuo Therapeutics reported strong Q1 revenue growth and reduced losses, but its critically low cash balance necessitated a $1.0 million loan for working capital, raising significant going concern doubts.


Key Events · Financing and Capital Events · AURX

  • Strong Q1 2026 Revenue Growth

    Total revenues increased 169% year-over-year to $1.3 million, with product revenues up over 30% sequentially.

  • Reduced Net Operating Loss

    Net operating loss decreased to $446,000 in Q1 2026, compared to $745,000 in Q1 2025.

  • Critical Cash Position

    Cash balance dropped to $263,827 by March 31, 2026, from $548,946 at December 31, 2025, indicating significant cash burn.

  • Secured $1.0 Million Loan

    The company entered into a Loan and Security Agreement with initial funding of $1.0 million to provide working capital.


Analysis · AURX · Industrial Applications And Services

This 8-K reports Nuo Therapeutics' Q1 2026 financial results, showing strong revenue growth and reduced operating losses. However, the company's cash position is critically low, necessitating a $1.0 million loan for working capital. This financial distress, coupled with the significant going concern doubts highlighted in the full Q1 report, indicates a precarious financial situation despite operational improvements. The loan is a short-term lifeline but underscores the company's urgent need for capital.

How filings like this one have moved

In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AURX was trading at $1.35 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $65.2M. The 52-week trading range was $0.94 to $3.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AURX - Latest Insights

AURX
Aug 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $1.25 info
Change: +$0.480 (+62%) info
Market Cap: $60.542M info
AURX
Aug 17, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $1.25 info
Change: +$0.480 (+62%) info
Market Cap: $60.542M info
AURX
Aug 14, 2026, 5:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.770
Real-time Price: $1.25 info
Change: +$0.480 (+62%) info
Market Cap: $60.542M info
AURX
Jun 03, 2026, 11:04 AM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $1.25 info
Change: +$0.190 (+18%) info
Market Cap: $60.542M info
AURX
Jun 03, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $1.25 info
Change: +$0.180 (+17%) info
Market Cap: $60.542M info